Pipeline, and what Intangia found around it
A partner's early-stage pipeline read against the field it has to win in: how crowded each indication already is, how many rivals are further ahead, whether there is still room to be first or best in class, and what the regulator will actually approve. Alongside it, the new programme ideas Intangia surfaces by watching the literature, patent and clinical record around those same targets.
Open report → Validation · Technical preprintThe signal before the trial
Evidence that Intangia's triage layer anticipates clinical entry: a temporally controlled replay with scoring cutoffs from 2010 to 2023 across 100 disease and target areas, using only records dated at or before each historical cutoff. A 1-in-4 top-20 shortlist hit rate, named PD-1 and CTLA-4 alerts, and breadth scores.
Open report → ADC / TCE / CAR-T · CRC & LungColorectal & lung surface targets, three-modality
Cell-surface targets in colorectal cancer, NSCLC and SCLC, scored for antibody-drug-conjugate, T-cell-engager and CAR-T developability. A per-target modality-fit heatmap shows which format each target favours, plus mature and novel lists and the full developable set.
Open report → ADC / TCE · CRC & LungColorectal & lung surface targets
Cell-surface targets in colorectal cancer, NSCLC and SCLC, prioritised for antibody-drug-conjugate and T-cell-engager developability. Mature and novel lists plus the full developable set.
Open report → Indications · Unmet NeedDisease unmet-need landscape
1,000 indications scored and ranked by therapeutic unmet need — treatment landscape, prevalence and pipeline depth — then enriched with genetic targets, modalities and mechanisms. Full ranked table, top-40 detail, and a burden × therapy-gap map.
Open report →